Boston Scientific (NY:BSX)

42.60 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

30 31 Next >

$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,200 Today ↗

March 08, 2024

Via Benzinga

17 Analysts Have This To Say About Boston Scientific ↗

March 07, 2024

Via Benzinga

The Hot List: 3 AI Stocks Worth Buying on Weakness ↗

March 01, 2024

Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.

Via InvestorPlace

Topics Artificial Intelligence

Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect ↗

February 27, 2024

Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today ↗

February 22, 2024

Via Benzinga

$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today ↗

February 12, 2024

Via Benzinga

Boston Scientific Options Trading: A Deep Dive into Market Sentiment ↗

February 07, 2024

Via Benzinga

Key Takeaways From Boston Scientific Analyst Ratings ↗

February 01, 2024

Via Benzinga

Preview: Boston Scientific's Earnings ↗

January 30, 2024

Via Benzinga

Citadel Is The Most Successful Hedge Fund In History: Here Are Its Top Investment Picks ↗

February 16, 2024

Via Benzinga

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

Boston Scientific Corp. (NYSE: BSX) Sets New 52-Week High in Friday Session

February 02, 2024

Via Investor Brand Network

Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years ↗

February 01, 2024

Via Benzinga

Looking Into Boston Scientific's Recent Short Interest ↗

January 23, 2024

Via Benzinga

Demystifying Boston Scientific: Insights From 10 Analyst Reviews ↗

January 16, 2024

Via Benzinga

Stryker Stock Sees Relative Strength Rating Jump To 84 ↗

February 01, 2024

The Relative Strength (RS) Rating for Stryker stock jumped into a new percentile Thursday, with a rise from 76 to 84.

Via Investor's Business Daily

AT&T To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 01, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Biotech And Medtech Portfolio Notes On A Fed Day ↗

January 31, 2024

The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%

Via Talk Markets

Topics Economy

Nasdaq, S&P 500 Slip Ahead Of Fed Meeting, Regional Banks Sink After NYCB Disappoints: What's Driving Markets Wednesday? ↗

January 31, 2024

Nasdaq down 1.4%, S&P 500 down 0.9%, Dow up: Volatile day on Wall Street as tech stocks react to disappointing earnings ahead of Fed meeting.

Via Benzinga

Topics Economy Stocks

Why Medical Devices Giant Boston Scientific Shares Are Rising Today ↗

January 31, 2024

Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlook for 2024.

Via Benzinga

Boston Scientific Surges On Its 'Impressive' First-Quarter Guidance ↗

January 31, 2024

The company expects sales to grow 7% to 9% organically, above expectations.

Via Investor's Business Daily

Stryker, Boston Scientific Score Earnings Beats, Extend Breakouts ↗

January 31, 2024

Shares of Stryker, Boston Scientific jumped early Wednesday after healthy earnings beats and price target hikes from analysts.

Via Investor's Business Daily

Topics Earnings

Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗

January 31, 2024

The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.

Via Benzinga

Topics Economy

Earnings Scheduled For January 31, 2024 ↗

January 31, 2024

Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.

Via Benzinga

Boston Scientific Corporation Should Continue Uptrend & Remain Supported ↗

January 30, 2024

Boston Scientific Corporation develops, manufactures & markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg & Cardiovascular segments.

Via Talk Markets

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst ↗

January 23, 2024

Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.

Via Benzinga

Chart Of The Day: Boston Scientific - Revenue Growth Potential ↗

January 18, 2024

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

Via Talk Markets

Palo Alto Networks, Nvidia, And 2 Other Stocks Insiders Are Selling ↗

January 17, 2024

The Nasdaq 100 closed slightly lower on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

January 16, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.